[Congress] 1st Microbiome Movement Oncology Response - 22-24 July - Boston

1st Microbiome Movement Oncology Response – 22-24 Juillet – Boston

[New offering] Oncodesign can support the development of your microbiota-based therapeutics!

At the occasion of the Microbiome Movement Oncology Response, meet Francis Bichat, Technology Director and Sylvie Maubant, Study Director to discuss custom-made models & assays for your in vitro & in vivo studies.

We will shed the light on our wide range of expertise to assess the effect of your microbiota-based therapeutics cross therapeutic areas including oncology, inflammatory diseases & infectious diseases!

I fix a meeting!

 

Nos expert seront présents:

Table ronde "Quoi de neuf autour de l’innovation en oncologie ? » Avec la participation de Mr. Sébastien Vachenc Responsable Data Sciences et Directeur de projet OncoSNIPE®

Session de Networking où nous dévoilerons nos compétences en oncologie/IO dans le cadre de notre consortium IMODI ainsi que notre large palette d’offres pour les maladies inflamatoires et maladies infectieuses ( depuis l’identification de cibles, la phase d’optimisation à la demande d’investigation du nouveau medicament (IND))

Oncodesign vous guide tout au long des processus de développement de votre candidat médicament.
A l'occasion du congrès annuel SNMMI, nous vous dévoilons notre expertise en pharmaco-imagerie et radiothérapie ciblée.

[Congress] 7th Annual Predict: Tumor Models - 16-18 July - Boston - USA

7th Annual Predict Tumor models - 16-18 July - Boston - USA

Our experts will be at the congress Predict Tumor Models!

Discover or rediscover our vivo (PDX, syngeneic) and preclinical in vitro models, as predictive tools for the efficacy of your molecules in immuno-oncology.

Schedule a meeting to discuss your project and investigate how Oncodesign can support your pipeline!

This email address is being protected from spambots. You need JavaScript enabled to view it.


Venez discuter de notre large palette de services et solutions innovantes & les opportunités de licensing ou partenariat en oncologie, immuno-inflammation& maladie neurodégénératives.

[Congress] #SNMMI19 Annual Meeting – 22-25 June – California

Congres SNMMI2019 California – 22-25 June

Oncodesign guides you throughout the drug development process to figure out how your compound works and reaches the right patient.
We unveil our expertise in Pharmaco-imaging and Targeted Radiotherapy (TRT)?

Meet Scott Barksdale during the SNMMI Annual Meeting to explore our multi-modal pharmaco-imaging  and targeted radiotherapy expertise for your preclinical projects.

  • Design & implementation of the radionuclide labeling of your chemical or biological molecules of interest
  • Biodistribution of therapeutic drugs using non-invasive techniques
  • Development of translational #nuclearmedicine #biomarkers
  • Evaluation of targeted radiotherapy efficacy

Moreover, Oncodesign can help leverage your preclinical targeted  #radiotherapy program!
Our experts can manage a complete  #preclinical targeted radiopharmaceuticals project, including combination studies with  #DNA damage inhibitor or #Immune_checkpoint  #inhibitors!
We offer cutting-edge technology & cross expertise with other therapies and models. 

I fix a meeting!


Venez discuter de notre large palette de services et solutions innovantes & les opportunités de licensing ou partenariat en oncologie, immuno-inflammation& maladie neurodégénératives.

Nos expert seront présents:

Table ronde "Quoi de neuf autour de l’innovation en oncologie ? » Avec la participation de Mr. Sébastien Vachenc Responsable Data Sciences et Directeur de projet OncoSNIPE®

Session de Networking où nous dévoilerons nos compétences en oncologie/IO dans le cadre de notre consortium IMODI ainsi que notre large palette d’offres pour les maladies inflamatoires et maladies infectieuses ( depuis l’identification de cibles, la phase d’optimisation à la demande d’investigation du nouveau medicament (IND))

 

[Congress] Biotech Outsourcing Strategies - 19-20 June - Basel 

[Congress] Biotech Outsourcing Strategies - 19-20 June - Basel - Switzerland

BOS meeting, the must-be place to share experience, develop knowledge and skills and build new and existing business partnerships!

Christophe Parsy, Drug Discovery Business Development Director and Mouhssin Oufir, DMPK & Bioanalytical Sciences Department Head, will be attending the Biotech Outsourcing Meeting.

We propose our Research and Development expertise in small molecules for any company to outsource new drug candidate generation by providing an Integrated Drug Discovery Service as a package or on a fee for service basis including:

  • Medicinal Chemistry
  • Pharmacology
  • DMPK
  • Safety and Toxicity 

Throughout your drug development process, we also offer you:

  • Our integrated Bioanalysis Service in GPx environment for both NCE & biologics:
    • Analysis of your New Chemical and Biological Entities
    • Analysis of membrane proteins
    • Immuno-analysis
  • Our DMPK expertise 
    • Early in vitro/in vivo ADME
    • Animal Pk and metabolism
    • Human Pk and metabolism

Arrange a meeting direcly on the B2B platform to meet our experts. 

I fix a meeting!


Venez discuter de notre large palette de services et solutions innovantes & les opportunités de licensing ou partenariat en oncologie, immuno-inflammation& maladie neurodégénératives.

Nos expert seront présents:

Table ronde "Quoi de neuf autour de l’innovation en oncologie ? » Avec la participation de Mr. Sébastien Vachenc Responsable Data Sciences et Directeur de projet OncoSNIPE®

Session de Networking où nous dévoilerons nos compétences en oncologie/IO dans le cadre de notre consortium IMODI ainsi que notre large palette d’offres pour les maladies inflamatoires et maladies infectieuses ( depuis l’identification de cibles, la phase d’optimisation à la demande d’investigation du nouveau medicament (IND))

 

By closing this message, you consent to our cookies on this device in accordance with our cookie policy unless you have disabled them.